Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prostate cancer and the role of biomarkers.

Nevo A, Navaratnam A, Andrews P.

Abdom Radiol (NY). 2019 Nov 13. doi: 10.1007/s00261-019-02305-8. [Epub ahead of print] Review.

PMID:
31720770
2.

Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.

PMID:
29129398
3.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

4.

The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer.

Abdollah F, Dalela D, Haffner MC, Culig Z, Schalken J.

Eur Urol Focus. 2015 Sep;1(2):99-108. doi: 10.1016/j.euf.2015.08.001. Epub 2015 Aug 28. Review.

PMID:
28723439
5.

Biomarkers for Prostate Biopsy and Risk Stratification of Newly Diagnosed Prostate Cancer Patients.

Loeb S.

Urol Pract. 2017 Jul;4(4):315-321. doi: 10.1016/j.urpr.2016.08.001. Epub 2016 Oct 22.

6.

Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification.

Loeb S, Bruinsma SM, Nicholson J, Briganti A, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ.

Eur Urol. 2015 Apr;67(4):619-26. doi: 10.1016/j.eururo.2014.10.010. Epub 2014 Oct 31. Review.

7.

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H.

Eur Urol. 2011 Nov;60(5):1045-54. doi: 10.1016/j.eururo.2011.08.003. Epub 2011 Aug 25. Review.

PMID:
21871709
8.
9.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

10.

Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C.

Minerva Urol Nefrol. 2015 Sep;67(3):211-31. Epub 2015 Jun 9. Review.

PMID:
26054411
11.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
12.

Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.

Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.

Eur Urol. 2018 Aug;74(2):211-217. doi: 10.1016/j.eururo.2018.01.017. Epub 2018 Feb 9.

13.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

14.

New biomarkers for diagnosis and prognosis of localized prostate cancer.

Chistiakov DA, Myasoedova VA, Grechko AV, Melnichenko AA, Orekhov AN.

Semin Cancer Biol. 2018 Oct;52(Pt 1):9-16. doi: 10.1016/j.semcancer.2018.01.012. Epub 2018 Jan 31. Review.

PMID:
29360504
15.

[The level of evidence for the use of biomarkers in the early detection of prostate cancer].

Lamy PJ, Gauchez AS, Salomon L, Haugh M, Ceraline J, Fulla Y, Georges A, Larré S, Loric S, Luporsi E, Martin PM, Mazerolles C, Molinié V, Mongiat-Artus P, Piffret J, Thuillier F, Perrin P, Rebillard X; Groupe de biologie de la prostate.

Ann Biol Clin (Paris). 2016 Mar-Apr;74(2):227-32. doi: 10.1684/abc.2016.1128. Review. French.

16.

A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.

Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R, Hanna MY, Mills R, Tuzova AV, O'Reilly E, Kelly S, Cooper C; Movember Urine Biomarker Consortium, Brewer D, Perry AS, Clark J, Fleshner N, Bapat B.

Clin Epigenetics. 2018 Nov 23;10(1):147. doi: 10.1186/s13148-018-0575-z.

17.

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.

Bangma CH, van Schaik RH, Blijenberg BG, Roobol MJ, Lilja H, Stenman UH.

Eur J Cancer. 2010 Nov;46(17):3109-19. doi: 10.1016/j.ejca.2010.09.031.

PMID:
21047594
18.

Prostate specific antigen. Current clinical application and future prospects.

Duskova K, Vesely S.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):18-26. doi: 10.5507/bp.2014.046. Epub 2014 Oct 2. Review.

19.

Preoperative Prostate-specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer: Results from a Multicentric European Prospective Study.

Fossati N, Buffi NM, Haese A, Stephan C, Larcher A, McNicholas T, de la Taille A, Freschi M, Lughezzani G, Abrate A, Bini V, Palou Redorta J, Graefen M, Guazzoni G, Lazzeri M.

Eur Urol. 2015 Jul;68(1):132-8. doi: 10.1016/j.eururo.2014.07.034. Epub 2014 Aug 16.

PMID:
25139197
20.

Review of diagnostic markers for prostate cancer.

Schröder FH.

Recent Results Cancer Res. 2009;181:173-82. Review.

PMID:
19213567

Supplemental Content

Support Center